findphrase.net
 

Phrases contain exact "meningococcal acwy" from credible sources

EXACT :

Background: In August, 2015, the UK implemented an emergency adolescent immunisation programme with the meningococcal ACWY conjugate vaccine to combat a national outbreak of meningococcal group W (MenW) disease due to a hypervirulent ST-11 complex strain, which is currently causing regional and national outbreaks worldwide. This immunisation programme …
pubmed.ncbi.nlm.nih.gov


Jun 17, 2019 · Background: After the introduction of the meningococcal ACWY-CRM197 conjugate vaccine (MenACWY-CRM) in 2012 and the meningococcal ACWY-diphtheria toxoid conjugate vaccine (MenACWY-DT) in 2014, immunization was recommended for certain high-risk groups including new military recruits in Korea. However, comparative immunogenicity studies …
pubmed.ncbi.nlm.nih.gov


Introduction: Menveo, quadrivalent meningococcal ACWY-CRM conjugate vaccine, was first licensed in 2010 in the United States and has a long track record of immunogenicity and safety in all age groups, including infants from 2 months of age. Areas covered: This review presents clinical and post-marketing experience with MenACWY-CRM from 32 studies conducted in 20 …
pubmed.ncbi.nlm.nih.gov


Aug 03, 2021 · In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16-19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended for teenagers with out-o …
pubmed.ncbi.nlm.nih.gov


During the first 12 months of an emergency meningococcal ACWY vaccination program for teenagers in England, coverage among persons who left school in 2015, the first cohort to be vaccinated, was 36.6%. There were 69% fewer group W meningococcal cases than predicted by trend analysis and no cases in …
pubmed.ncbi.nlm.nih.gov


MenACYW-TT (MenQuadfi®) is a quadrivalent meningococcal tetanus toxoid conjugate vaccine licensed in Europe for use in individuals ≥12 months. This study assessed whether serogroup C immune responses with MenACYW-TT were at least non-inferior, or superior, to those of quadrivalent meningococcal ACWY
pubmed.ncbi.nlm.nih.gov


Aug 06, 2021 · <strong>Meningococcal ACWY</strong> vaccine can help protect against<strong> meningococcal</strong> disease caused by serogroups A, C, W, and Y. A different<strong> meningococcal</strong> vaccine is available that …
www.cdc.gov


Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can help …
medlineplus.gov


May 18, 2021 · Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can …
www.healthychildren.org


Jan 12, 2022 · View All Meningococcal ACWY Handouts. Vaccine Information Statements. VISs are information sheets produced by CDC that explain both the benefits and risks of a vaccine …
www.immunize.org


Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can help …
healthy.kaiserpermanente.org


Aug 12, 2021 · Meningococcal ACWYvaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can …
www.mountsinai.org


<strong>Meningococcal ACWY</strong> vaccinecan help protect against<strong> meningococcal</strong> disease caused by serogroups A, C, W, and Y. A different<strong> meningococcal</strong> vaccine is available that can help …
lancastergeneralhealth.org


Oct 14, 2020 · <strong>Meningococcal ACWY</strong> Disease Issues Please tell us about<strong> meningococcal</strong> disease.<strong> Meningococcal</strong> disease is a bacterial infection caused by Neisseria meningitidis.<strong></strong> …
www.immunize.org


The meningococcal ACWY vaccine is a safe and effective way to help protect young people from meningococcal disease. Meningococcal ACWY vaccination programs have been in place for …
www.health.gov.au


Dec 03, 2019 · Meningococcal ACWY In this topic Meningococcal disease is a disease caused by a bacterium, the meningococcus. There are several types of this bacterium. Types A, B, C, W …
www.rivm.nl


Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can help …
vickeryvaccine.com


Feb 19, 2019 · What is meningococcal ACWY & how do you catch it? Meningococcal disease is caused by bacteria and can result in meningitis, an infection of the membranes that surround …
www.boots.com


Meningococcal ACWY vaccine Meningococcal is a rare but life threatening disease. A free meningococcal ACWY vaccine is available for children aged 1 to 4 and young people 15 to 19 …
www.healthywa.wa.gov.au


Meningococcal ACWY vaccines can help prevent meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available to help protect against …
dc.statelibrary.sc.gov


Introduction: Menveo, quadrivalent <strong>meningococcal ACWY</strong>-CRM conjugate vaccine, was first licensed in 2010 in the United States and has a long track record of immunogenicity and safety in all age groups, including infants from 2 months of age. Areas covered: This review presents clinical and post-marketing experience with MenACWY-CRM from 32 studies conducted in 20 … <br><strong>Author:</strong> Pavitra Keshavan, Michele Pellegrini, Kumaran Vadivelu-Pechai, Michael Nissen <br><strong>Publish Year:</strong> 2018
pubmed.ncbi.nlm.nih.gov


Background: In August, 2015, the UK implemented an emergency adolescent immunisation programme with the <strong>meningococcal ACWY</strong> conjugate vaccine to combat a national outbreak of <strong>meningococcal</strong> group W (MenW) disease due to a hypervirulent ST-11 complex strain, which is currently causing regional and national outbreaks worldwide. This immunisation programme …
pubmed.ncbi.nlm.nih.gov


Jan 18, 2017 · A new MenACWY conjugate <strong>meningococcal</strong> vaccination programme was introduced in Northern Ireland (NI) in August 2015, for 13-18 year olds, as well as for first-time university entrants up to 25 years. ... <strong>Meningococcal ACWY</strong> vaccine uptake and awareness among student freshers enrolled at Northern Ireland universities Int J Adolesc Med Health. …
pubmed.ncbi.nlm.nih.gov


During the first 12 months of an emergency <strong>meningococcal ACWY</strong> vaccination program for teenagers in England, coverage among persons who left school in 2015, the first cohort to be vaccinated, was 36.6%. There were 69% fewer group W <strong>meningococcal</strong> cases than predicted by trend analysis and no cases in …
pubmed.ncbi.nlm.nih.gov


Aug 06, 2021 · Meningococcal ACWY vaccine can help protect against<strong> meningococcal disease</strong> caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can …
www.cdc.gov


Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can help …
medlineplus.gov


<strong>Meningococcal ACWY</strong> vaccine can help protect against <strong>meningococcal</strong> disease caused by serogroups A, C, W, and Y. A different <strong>meningococcal</strong> vaccine is available that can help …
lancastergeneralhealth.org


Oct 14, 2020 · Meningococcal ACWY Disease Issues Please tell us about meningococcal disease. Meningococcal disease is<strong> a bacterial infection caused by Neisseria meningitidis.</strong> …
www.immunize.org


<strong>Meningococcal ACWY</strong> vaccine for adolescents and specific populations. MenB <strong>Meningococcal</strong> B vaccine for adolescents and adults of specific populations. Available Vaccines. There are …
www.cdc.gov


Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can help …
healthy.kaiserpermanente.org


Jun 03, 2022 · SPANISH. Standing orders for administering <strong>meningococcal ACWY</strong> vaccine to adults. Eligible healthcare professionals may vaccinate adults who meet any of the criteria on …
www.immunize.org


Jan 12, 2022 · View All <strong>Meningococcal ACWY</strong> Handouts. Vaccine Information Statements. VISs are information sheets produced by CDC that explain both the benefits and risks of a vaccine …
www.immunize.org


<strong>Meningococcal ACWY</strong> vaccine. Adolescents need 2 doses of a <strong>meningococcal ACWY</strong> vaccine: First dose: 11 or 12 year of age. Second (booster) dose: 16 years of age. In addition to routine …
www.healthychildren.org


<strong>meningococcal ACWY</strong> vaccine. Your health care provider can give you more information. 4. Risks of a vaccine reaction Redness or soreness where the shot is given can happen after …
www.cdc.gov


The meningococcal ACWY vaccine is a safe and effective way to help protect young people from meningococcal disease. Meningococcal ACWY vaccination programs have been in place for …
www.health.gov.au


<strong>Meningococcal ACWY</strong> v accine . MIIC vaccine ID Generic name Trade name CPT code CVX code . 119 MenACWY-D Menactra 90734 114 151 MenACWY -CRM Menveo 90734 136 221 …
www2.web.health.state.mn.us


Meningococcal ACWY vaccine Meningococcal is a rare but life threatening disease. A free meningococcal ACWY vaccine is available for children aged 1 to 4 and young people 15 to 19 …
www.healthywa.wa.gov.au


Phrases contain similar "meningococcal acwy" from credible sources

SIMILAR :

Objective: This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent meningococcal disease from serogroups A, C, W, Y. Data sources: A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, … <br><strong>Author:</strong> Jessica Huston, Kevin Galicia, Eric F Egelund <br><strong>Publish Year:</strong> 2021
pubmed.ncbi.nlm.nih.gov


Jul 06, 2022 · Background: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 14-18 years was executed. We investigated …
pubmed.ncbi.nlm.nih.gov


Jul 01, 2009 · Background: Neisseria meningitidis is an important cause of invasive bacterial infection in the United States, and disease rates are higher for adolescents than for the general population. Quadrivalent meningococcal conjugate vaccine is recommended for routine vaccination of adolescents and high-risk groups. This study compares the safety and … <br><strong>Author:</strong> Lisa A. Jackson, Roger Baxter, Keith Reisinger, Annette Karsten, Jina Shah, Lisa Bedell, Peter M. Du... <br><strong>Publish Year:</strong> 2009
pubmed.ncbi.nlm.nih.gov


Dec 13, 2014 · Background: Meningococcal conjugate vaccines protect individuals directly, but can also confer herd protection by interrupting carriage transmission. We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates in 18-24-year-olds. <br><strong>Author:</strong> Robert C Read, David Baxter, David R Chadwick, Saul N Faust, Saul N Faust, Adam Finn, Stephen B Gord... <br><strong>Publish Year:</strong> 2014
pubmed.ncbi.nlm.nih.gov


Neisseria meningitidis is the leading cause of bacterial invasive infections in people aged <15 years in the Russian Federation. The aim of this phase III, multicenter, open-label study was to assess the immunogenicity and safety of the quadrivalent meningococcal CRM197-conjugate vaccine MenACWY when administered to healthy Russian subjects aged 2 years and above.
pubmed.ncbi.nlm.nih.gov


The UK MenACWY vaccination programme reduced carriage acquisition of genogroup and serogroup Y and W meningococci and sustained low levels of genogroup C carriage. These data support the use of quadrivalent MenACWY conjugate vaccine for indirect (herd) protection.
pubmed.ncbi.nlm.nih.gov


Jan 11, 2017 · Background: University students have high rates of pharyngeal carriage of Neisseria meningitidis. Interruption of carriage acquisition is an important mechanism of vaccines for inducing herd protection. 4CMenB and MenACWY-CRM vaccines have been shown to be immunogenic against meningococcal serogroups B and ACWY respectively in younger age …
pubmed.ncbi.nlm.nih.gov


Jun 26, 2015 · Safety precautions for laboratory staff working with meningococci should primarily rely on laboratory procedures preventing exposure to aerosols containing viable meningococci. Despite this, vaccination is a key component of protection in the occupational setting. In the UK in 2009, there were no li …
pubmed.ncbi.nlm.nih.gov


Bacterial capsular polysaccharide<strong> vaccines</strong> are generally poorly immunogenic in infants and older adults. The immunogenicity of capsular polysaccharide<strong> vaccines</strong> can be improved by conjugating them to immunogenic carrier proteins. One of the most recently licensed conjugate<strong> vaccines</strong> is the quadrivalen …
pubmed.ncbi.nlm.nih.gov


Background: Infants are at the highest risk for meningococcal disease and a broadly protective and safe vaccine is an unmet need in this youngest population. We evaluated the immunogenicity and safety of a 4-dose infant/toddler regimen of MenACWY-CRM given at 2, 4, 6, and 12 months of age concomitantly with pentavalent diphtheria-tetanus-acellular pertussis-Hemophilus …
pubmed.ncbi.nlm.nih.gov


Jul 22, 2020 · Background: Between 2015 and 2018 the incidence of meningococcal disease serogroup W increased tenfold in the Netherlands with the highest case fatality among adolescents and young adults. In 2018-2019 a national mass vaccination campaign, with recall after non-attendance, was implemented targeting 14-18-years old adolescents.
pubmed.ncbi.nlm.nih.gov


Introduction: Meningococcal disease caused by Neisseria meningitidis is a major cause of meningitis and septicemia with high rates of morbidity and mortality worldwide. MenACWY-TT and MenACWY-CRM 197 are meningococcal conjugate vaccines approved for use in children and adults in the UK. The aim of this review was to evaluate and compare antibody responses and …
pubmed.ncbi.nlm.nih.gov


Background: An investigational quadrivalent Neisseria meningitidis serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) has been developed to expand available options for vaccination against invasive meningococcal disease. Methods: A total of 784 healthy adolescents and young adults 11 to 25 years of age were randomized (3:1) to receive a single …
pubmed.ncbi.nlm.nih.gov


Invasive meningococcal disease is a rare but serious infection caused by Neisseria meningitidis Serogroup B was the predominant serogroup causing invasive meningococcal disease in Australia until 2015. Serogroup W disease has increased substantially since 2014, and in 2017, serogroups B and W caused …
pubmed.ncbi.nlm.nih.gov



medlineplus.gov


<strong>Meningococcal</strong> conjugate or<strong> MenACWY</strong> vaccines (Menactra ® , Menveo ®, and MenQuadfi ®) Serogroup B<strong> meningococcal</strong> or MenB vaccines (Bexsero ® and Trumenba ®) All 11 to 12 …
www.cdc.gov


Apr 19, 2022 · The meningitis ACWY (MenACWY) vaccine helps protect against meningitis and septicaemia (blood poisoning) caused by 4 groups of meningococcal bacteria A, C, W and Y. …
www.nhsinform.scot


MenACWY vaccines are safe to use with most other vaccines given in childhood 11-21 and adolescence. 22-26 In most studies, the frequency of reactions after vaccination was similar …
immunisationhandbook.health.gov.au


Jun 26, 2015 · The MenACWY vaccine is being introduced in response to an increase in cases of invasive meningococcal disease capsular group W ( MenW) disease. This vaccine will provide …
www.gov.uk


Jul 12, 2022 · Meningococcal disease is a contagious disease caused by a bacterium called Neisseria meningitidis (also known as meningococcal bacteria). It can develop quickly, and it …
www.health.gov.au


Jan 28, 2022 · Background: A serogroup W (MenW) outbreak in Chile prompted a <strong>meningococcal</strong> vaccination campaign using tetravalent <strong>meningococcal</strong>-conjugate vaccines (MCV-<strong>ACWY</strong>) in children since 2012, followed by its introduction into the National Immunization Program (NIP) in toddlers from 2014. Direct protection was observed, but no indirect effects in …
pubmed.ncbi.nlm.nih.gov


Objective: This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent <strong>meningococcal</strong> disease from serogroups A, C, W, Y. Data sources: A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, … <br><strong>Author:</strong> Jessica Huston, Kevin Galicia, Eric F Egelund <br><strong>Publish Year:</strong> 2021
pubmed.ncbi.nlm.nih.gov


Invasive <strong>meningococcal</strong> disease (IMD) is caused by 6 serogroups of the bacterium Neisseria meningitidis (A, B, C, W, X and Y). It is among the most serious vaccine preventable infectious diseases, characterized by a high case-fatality rate and risk of permanent sequelae. ... Y. Currently four <strong>ACWY</strong> quadrivalent conjugate vaccines are available ...
pubmed.ncbi.nlm.nih.gov


Jul 06, 2022 · Background: In response to the recent serogroup W invasive <strong>meningococcal</strong> disease (IMD-W) epidemic in the Netherlands, <strong>meningococcal</strong> serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 14-18 years was executed. We investigated …
pubmed.ncbi.nlm.nih.gov


May 15, 2015 · Background: A <strong>meningococcal</strong> vaccine protective against all major disease-associated serogroups (A, B, C, W and Y) is an unmet public health need. In this phase 2 observer-blinded, randomized, controlled study, two investigational <strong>meningococcal</strong> ABCWY vaccine formulations were evaluated to assess their immunological noninferiority to a licensed …
pubmed.ncbi.nlm.nih.gov


Dec 13, 2014 · Background: <strong>Meningococcal</strong> conjugate vaccines protect individuals directly, but can also confer herd protection by interrupting carriage transmission. We assessed the effects of <strong>meningococcal</strong> quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on <strong>meningococcal</strong> carriage rates in 18-24-year-olds.
pubmed.ncbi.nlm.nih.gov


The UK MenACWY vaccination programme reduced carriage acquisition of genogroup and serogroup Y and W meningococci and sustained low levels of genogroup C carriage. These data support the use of quadrivalent MenACWY conjugate vaccine for indirect (herd) protection.
pubmed.ncbi.nlm.nih.gov


Jun 26, 2015 · In the UK in 2009, there were no licensed vaccines for <strong>meningococcal</strong> capsular group B or conjugate vaccines for capsular groups A, C, W and Y. We therefore undertook a Phase II trial in laboratory workers to investigate the safety and immunogenicity of a four component group B vaccine (4CMenB) and a quadrivalent group A, C, W and Y conjugate ...
pubmed.ncbi.nlm.nih.gov


Introduction: <strong>Meningococcal</strong> disease caused by Neisseria meningitidis is a major cause of meningitis and septicemia with high rates of morbidity and mortality worldwide. MenACWY-TT and MenACWY-CRM 197 are <strong>meningococcal</strong> conjugate vaccines approved for use in children and adults in the UK. The aim of this review was to evaluate and compare antibody responses and …
pubmed.ncbi.nlm.nih.gov


Jun 16, 2017 · A physicochemical and immunological study of the stability of three different <strong>meningococcal</strong> (Men) <strong>ACWY</strong> conjugate vaccines was performed to evaluate any patterns of serogroup oligo- or polysaccharide-specific or carrier protein-specific stability that would affect immunogenicity. Critical quality and stability-indicating characteristics were ...
pubmed.ncbi.nlm.nih.gov


Neisseria meningitidis is the leading cause of bacterial invasive infections in people aged <15 years in the Russian Federation. The aim of this phase III, multicenter, open-label study was to assess the immunogenicity and safety of the quadrivalent <strong>meningococcal</strong> CRM197-conjugate vaccine MenACWY when administered to healthy Russian subjects aged 2 years and above.
pubmed.ncbi.nlm.nih.gov


Background: Infants are at the highest risk for <strong>meningococcal</strong> disease and a broadly protective and safe vaccine is an unmet need in this youngest population. We evaluated the immunogenicity and safety of a 4-dose infant/toddler regimen of MenACWY-CRM given at 2, 4, 6, and 12 months of age concomitantly with pentavalent diphtheria-tetanus-acellular pertussis-Hemophilus …
pubmed.ncbi.nlm.nih.gov


Jun 27, 2018 · Background: Invasive <strong>meningococcal</strong> disease has a high burden in young children, particularly during infancy. We investigated the immunogenicity and safety of a quadrivalent <strong>meningococcal</strong> conjugated vaccine (MenACWY-TT) co-administered with routine vaccines in healthy infants.
pubmed.ncbi.nlm.nih.gov


Jul 22, 2020 · Background: Between 2015 and 2018 the incidence of <strong>meningococcal</strong> disease serogroup W increased tenfold in the Netherlands with the highest case fatality among adolescents and young adults. In 2018-2019 a national mass vaccination campaign, with recall after non-attendance, was implemented targeting 14-18-years old adolescents.
pubmed.ncbi.nlm.nih.gov



medlineplus.gov


Meningococcal conjugate or MenACWY vaccines (Menactra ® , Menveo ®, and MenQuadfi ®) Serogroup B meningococcal or MenB vaccines (Bexsero ® and Trumenba ®) All<strong> 11 to 12</strong> …
www.cdc.gov


<br><strong>Last updated:</strong> Aug 12, 2021
www.mountsinai.org


Vacuna meningocócica <strong>ACWY</strong>. Los adolescentes necesitan 2 dosis de la vacuna meningocócica <strong>ACWY</strong>: Primera dosis: a los 11 o 12 años. Segunda dosis (refuerzo): a los 16 años. Además …
medlineplus.gov


Administer MenACWY vaccines (Menactra ®, Menveo ®, or MenQuadfi ®) to adolescents as<strong> 1 primary dose at 11 to 12 years of age.</strong> Administer 1 booster dose at 16 years of age. The …
www.cdc.gov


<strong>Meningococcal</strong> vaccination for people in a special risk group Recommendations All infants, children and adults Any person from<strong> 6 weeks of</strong> age who wants to protect themselves against<strong></strong> …
immunisationhandbook.health.gov.au


Apr 19, 2022 · The meningitis <strong>ACWY (MenACWY)</strong> vaccine helps protect against meningitis and septicaemia (blood poisoning) caused by 4 groups of <strong>meningococcal</strong> bacteria A, C, W and Y. …
www.nhsinform.scot



meningococcal acwy

[meningococcal* acwy*]